Injection for treating hyperthyroidism

Abstract

The invention relates to an injection medicament for treating hyperthyroid, which comprises the following components by weight part: 2 to 5 milligrams of dexamethasone injection, 0.5 to 1 milligram of octreotide injection, and 10 to 20 milligrams of ciclosporin A. Immune preparations such as the dexamethasone injection, the octreotide injection, the ciclosporin A and the like are adopted for treating the hyperthyroid by locally injecting the thyroid, the volume of the tumid thyroid is remarkably shrunk, and the function of the thyroid basically recovers within two months, so the injection medicament has remarkable curative effect, and can remarkably improve the remission rate of hyperthyroid and reduce the rate of relapse. Serious abnormal change, hypothyroidism and parathyroid hypofunction are not caused, and laryngeal recurrent nerve injury is also not caused. Through more than 580 cases of clinical therapy in related hospitals, the volume of the tumid thyroid is remarkably shrunk after therapy, clinical symptoms disappear, allergic response and complications are not caused, the effective percentage is nearly 100 percent, and the cure rate is as high as 98 percent.

Description

technical field [0001] The invention relates to a Keyingsu injection for treating hyperthyroidism. Background technique [0002] Toxic diffuse goiter with hyperthyroidism, referred to as hyperthyroidism, is an autoimmune disease. Currently, there are several ways to treat hyperthyroidism: [0003] 1. Antithyroid drug (methimazole or propylthiouracil) treatment: insist on taking it for a long time, at least 1.5 to 2 years. The course of treatment is long, the remission rate is about 40-60%, and the recurrence rate is high. In the course of treatment, it is easy to cause liver function damage and agranulocytosis. Once agranulocytosis occurs, measures should be taken immediately, otherwise, severe infection may cause death. If liver function is impaired, transaminases and jaundice index increase, liver protection treatment should be strengthened. Therefore, changes in blood routine and liver function should be monitored regularly during medication. There are also individual...

AI Technical Summary

Problems solved by technology

[0006] 4. Thyroid artery interventional embolization treatment: In this treatment, the catheter is sent into the superior thyroid artery through the femoral artery under digital subtraction, and the embolic agent mixed with contrast agent is slowly injected until the blood flow basically stops, and the general embolism area can reach 80 -90%, which is similar to subtotal thyroidectomy. At present, this therapy is still immature clinically. If the embolization area is too large, it will cause hypothyroidism, and if there is too little embolism, the treatment will fail.

It cannot be promoted in clinical treatment and can only be used as a scientific research

[0007] In addition, in recent years, foreign countries have begun to use oral immunosuppressants to treat hyperthyroidism, but due to the large oral dose, obvious adverse reactions, and high cost, the clinical promotion is limited to a certain extent